Published in J Clin Pathol on August 01, 1991
Comparison of labelling by bromodeoxyuridine, MIB-1, and proliferating cell nuclear antigen in gastric mucosal biopsy specimens. J Clin Pathol (1994) 1.09
Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. Am J Pathol (1993) 1.04
Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression. Gut (1992) 0.99
Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer (1999) 0.97
Expression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: relevance to tumour characteristics and prognosis. J Clin Pathol (1998) 0.93
The abundance of Rad51 protein in mouse embryonic stem cells is regulated at multiple levels. Stem Cell Res (2012) 0.84
Are Japanese and European gastric cancer the same biological entity? An immunohistochemical study. Br J Cancer (1995) 0.84
Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms. Acta Neuropathol (1993) 0.83
Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today (1999) 0.83
Comparison of three cell cycle associated antigens as markers of proliferative activity and prognosis in breast carcinoma. J Clin Pathol (1993) 0.82
Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol (1993) 0.82
Proliferating cell nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer? Br J Cancer (1995) 0.81
Expression of proliferating cell nuclear antigen (PCNA) in gastric carcinoma: no evidence for prognostic value. J Clin Pathol (1994) 0.80
Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer (1996) 0.80
PCNA and Ki-67 labelling indices in pre-irradiated and post-irradiated astrocytomas: a comparative immunohistochemical analysis for evaluation of proliferative activity. Mol Pathol (1998) 0.80
Identifying gastric cancer related genes using the shortest path algorithm and protein-protein interaction network. Biomed Res Int (2014) 0.79
Proliferating cell nuclear antigen (PCNA) as a prognostic factor in non-Hodgkin's lymphoma. Br J Cancer (1992) 0.78
Comparison of proliferation rates assessed using "multiblock" and conventional tissue blocks of lung carcinoma. J Clin Pathol (1992) 0.78
Prognostic value and clinicopathological significance of proliferating cell nuclear antigen expression in gastric cancer: a systematic review and meta-analysis. Onco Targets Ther (2017) 0.75
Immunohistochemical detection of proliferating cell nuclear antigen in hepatocellular carcinoma. World J Gastroenterol (1997) 0.75
Interleukin-8 does not influence proliferation of the SGC7901 gastric cancer cell line. Oncol Lett (2014) 0.75
Value of PCNA and Ki67 staining in breast cancer. J Clin Pathol (1993) 0.75
Lead article: The prognostic significance of proliferating cell nuclear antigen (pcna) in laryngeal cancer. Indian J Otolaryngol Head Neck Surg (1998) 0.75
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand (1965) 22.65
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem (1983) 9.40
Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature (1987) 6.45
Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol (1990) 5.90
Identity of the proliferating cell nuclear antigen and cyclin. Nature (1984) 3.44
Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci (1990) 3.35
Gastric carcinoma. A pathobiological classification. Cancer (1977) 2.76
Review: assessment of cell proliferation in histological material. J Clin Pathol (1990) 2.41
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Ki-67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations. J Pathol (1988) 1.36
Growth fractions in gastric carcinomas determined with monoclonal antibody Ki-67. Cancer (1990) 0.96
Is DNA ploidy and proliferative activity of prognostic value in advanced gastric carcinoma? Hum Pathol (1991) 0.94
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Cancer. p53, guardian of the genome. Nature (1992) 16.36
The p53 pathway. J Pathol (1999) 6.79
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J (1990) 6.34
Regulation of the specific DNA binding function of p53. Cell (1992) 6.16
Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol (1990) 5.90
Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell (1985) 5.88
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
An immunoaffinity purification procedure for SV40 large T antigen. Virology (1985) 4.81
Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell (1993) 4.62
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 3.89
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49
SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature (1980) 3.44
Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci (1990) 3.35
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res (1994) 3.28
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods (1992) 3.23
High levels of p53 protein in UV-irradiated normal human skin. Oncogene (1993) 3.15
Using the polymerase chain reaction to modify expression plasmids for epitope mapping. Nucleic Acids Res (1989) 3.15
Two pathways for base excision repair in mammalian cells. J Biol Chem (1996) 3.01
Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 2.96
Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A (1997) 2.90
Abnormal patterns of mucus secretion in apparently normal mucosa of large intestine with carcinoma. Cancer (1974) 2.87
Mucins in the human gastrointestinal epithelium: a review. Invest Cell Pathol (1980) 2.82
Requirement for the replication protein SSB in human DNA excision repair. Nature (1991) 2.80
Nuclear protein with sequence homology to translation initiation factor eIF-4A. Nature (1988) 2.77
Use of monoclonal antibodies as probes of simian virus 40 T antigen ATPase activity. J Biol Chem (1981) 2.77
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 2.75
Infective endocarditis as part of psittacosis. Lancet (1971) 2.72
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
Value of histochemical reactions for mucosubstances in the diagnosis of certain pathological conditions of the colon and rectum. Gut (1969) 2.66
Eosinophilic infiltrates of the gastrointestinal tract. J Clin Pathol (1986) 2.59
Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med (1990) 2.57
A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol (1995) 2.57
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology (1993) 2.52
An immunochemical investigation of SV40 T antigens. 1. Production properties and specificity of rabbit antibody to purified simian virus 40 large-T antigen. Virology (1978) 2.49
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene (1991) 2.42
p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol (1994) 2.41
Review: assessment of cell proliferation in histological material. J Clin Pathol (1990) 2.41
Structure and function of SV40 large-T antigen. Philos Trans R Soc Lond B Biol Sci (1987) 2.37
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
Atrophy and apoptosis in the cyclical human endometrium. J Pathol (1976) 2.30
Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol (1990) 2.29
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A (1998) 2.28
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep (2001) 2.27
Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol (1993) 2.27
Allosteric activation of latent p53 tetramers. Curr Biol (1994) 2.25
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol (1997) 2.25
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene (2001) 2.14
In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol (1993) 2.07
DbpA: a DEAD box protein specifically activated by 23s rRNA. EMBO J (1993) 2.04
Mucous secretion in rat colonic mucosa during carcinogenesis induced by dimethylhydrazine. A morphological and histochemical study. Br J Cancer (1975) 2.01
Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature (1991) 1.99
Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene (1999) 1.98
Nuclear protein p68 is an RNA-dependent ATPase. EMBO J (1989) 1.98
p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet (1991) 1.95
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. Nucleic Acids Res (1992) 1.91
The prohibitin family of mitochondrial proteins regulate replicative lifespan. Curr Biol (1997) 1.86
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A (1997) 1.81
Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol (1987) 1.80
Microscopic colitis-a cause of chronic watery diarrhoea. Br Med J (Clin Res Ed) (1982) 1.78
Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology (1983) 1.78
Origins of the prestalk-prespore pattern in Dictyostelium development. Cell (1989) 1.78
A variant of intestinal metaplasia associated with gastric carcinoma: a histochemical study. Histopathology (1979) 1.76
Primary malignant lymphoma of the colon and rectum. A histopathological and immunohistochemical analysis of 45 cases with clinicopathological correlations. Histopathology (1988) 1.76
Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut (1991) 1.76
Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays (1995) 1.75
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol (1995) 1.75
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res (1999) 1.74
Microscopic colitis cases revisited. Gastroenterology (1993) 1.74
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res (2001) 1.73
Do we really need a higher necropsy rate? Lancet (1999) 1.71
Cancer. A death in the life of p53. Nature (1993) 1.70
The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays (1993) 1.70
p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts. Mol Cell Biol (1991) 1.69
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer (1990) 1.69
Isolation and analysis of the fission yeast gene encoding polymerase delta accessory protein PCNA. EMBO J (1992) 1.68
Molecular characterization of the hdm2-p53 interaction. J Mol Biol (1997) 1.64
Observer variation and discriminatory value of biopsy features in inflammatory bowel disease. Gut (1994) 1.64
Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut (1985) 1.64
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1. Oncogene (1995) 1.62
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol (1992) 1.62
Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol (1991) 1.58
The diagnostic value of mucosubstances in rectal biopsies from patients with ulcerative colitis and Crohn's disease. Gut (1970) 1.58